COCP Stock Risk & Deep Value Analysis

Cocrystal Pharma Inc

DVR Score

6.4

out of 10

Solid Pick

What You Need to Know About COCP Stock

We analyzed Cocrystal Pharma Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran COCP through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.

Updated Apr 2, 2026•Run Fresh Analysis →

COCP Risk Analysis & Red Flags

What Could Go Wrong

The lead drug candidate, CDI-988, could fail to demonstrate efficacy or safety in ongoing or future clinical trials. Given the early stage of development and the company's limited cash reserves ($7.7M against an annual burn of $8.2M), such a failure would likely necessitate further substantial share dilution or jeopardize the company's ability to continue operations without significant external financing.

Risk Matrix

Overall

Aggressive

Financial

High

Market

Medium

Competitive

Medium

Execution

Medium

Regulatory

High

Red Flags

⚠
Persistent negative cash flow requiring continuous financing rounds.
⚠
Ongoing share dilution (approximately 11% in 2025).
⚠
Early-stage clinical pipeline with high inherent risk of failure.
⚠
Dispute with UK CRO over Phase 2a study, potentially impacting future operations or cash.

Upcoming Risk Events

📅
Negative or inconclusive results from CDI-988 Phase 1b study
📅
Increased cash burn beyond current projections, necessitating further significant dilution
📅
Escalation or unfavorable resolution of the UK CRO dispute

When to Reconsider

🚪
Announced failure of a pivotal clinical trial for a lead asset (e.g., CDI-988 Phase 1b).
🚪
Quarterly cash burn significantly exceeds current annual rate of $8.2 million without new financing.
🚪
Further share dilution of 20% or more in a single event without commensurate pipeline advancement.

Unlock COCP Risk Analysis & Red Flags

Create a free account to see the full analysis

Investment Thesis

Cocrystal Pharma represents a high-risk, high-reward opportunity based on its novel antiviral pipeline targeting large, unmet medical needs (norovirus, influenza). Recent improvements in financial management (reduced cash burn) and clinical advancement (CDI-988 into Phase 1b) de-risk the investment slightly, offering significant upside potential if clinical milestones are met and future dilution is managed efficiently. Success of CDI-988 could trigger a substantial re-rating given the product's first-oral candidate status and the large market opportunity.

Is COCP Stock Undervalued?

Cocrystal Pharma continues to target significant antiviral markets with its proprietary platform. The recent 2025 annual report shows material positive developments: net loss narrowed by nearly 50% and cash used in operations halved, significantly improving its financial runway and addressing prior concerns about unsustainable cash burn. Furthermore, lead norovirus candidate CDI-988 has entered Phase 1b, providing a key clinical catalyst. While share dilution (11% YoY) and the overall early-stage nature of its pipeline remain high risks, the improved financial trajectory and clinical execution slightly enhance the probability of substantial per-share value creation. The path to 10x growth within 3-5 years, though still challenging due to the need for future financing, appears slightly less precarious.

Unlock the full AI analysis for COCP

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

COCP Price Targets & Strategy

12-Month Target

$3.50

Bull Case

$10.20

Bear Case

$0.45

Valuation Basis

Estimated re-rating to a $40M market capitalization upon positive Phase 1b results for CDI-988, assuming ~11.3M shares outstanding.

Entry Strategy

Accumulate positions between $0.80-$1.05, seeking to establish a core position before Phase 1b results are fully de-risked.

Exit Strategy

Take partial profits (e.g., 30-50%) if share price reaches $4.00-$5.00 post-catalyst; stop loss at $0.65 if clinical results disappoint or cash burn accelerates significantly.

Portfolio Allocation

2-4% for aggressive risk tolerance; not suitable for conservative or moderate portfolios.

Price Targets & Strategy

Upgrade to Premium for price targets and entry/exit strategies

Does COCP Have a Competitive Moat?

Moat Rating

⚪ None

Moat Trend

Stable (Potential to expand if clinical trials are successful and lead to strong patent protection).

Moat Sources

1 Identified

Intangible Assets/IP (proprietary drug discovery platform and specific drug candidates)

Currently, the moat is nascent and relies entirely on the successful development and patent protection of its drug candidates. Without approved products or significant market penetration, its durability is highly uncertain and subject to clinical and regulatory success.

Moat Erosion Risks

•Failure of clinical trials leading to loss of competitive IP advantage.
•Development of superior or alternative treatments by competitors.
•Challenges to intellectual property rights or patent expirations.

COCP Competitive Moat Analysis

COCP Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Neutral (No specific data provided to indicate strong sentiment trends.)

Institutional Sentiment

Neutral (No analyst coverage or institutional buy/sell data reported.)

Insider Activity (Form 4)

No Form 4 filings or insider buy/sell transactions reported in the last 90 days (January 3–April 2, 2026).

Options Flow

Normal options activity (No specific unusual options activity reported.)

Earnings Intelligence

Next Earnings

Estimated early May 2026 (for Q1 2026 results)

Surprise Probability

Low (No consensus estimates provided by analysts.)

Historical Earnings Pattern

Limited historical data due to the company's stage; stock price reactions to earnings are highly volatile and dependent on clinical updates.

Key Metrics to Watch

Current cash and working capital balanceNet cash used in operating activities (cash burn rate)Updates on clinical trial progress for CDI-988 and other pipeline candidates

Competitive Position

Top Competitor

N/A - No direct 'best-in-class' competitor mentioned in provided data for novel norovirus or influenza antivirals.

Market Share Trend

Not applicable as no commercial products are available.

Valuation vs Peers

Valuation metrics (P/E, P/S) are not applicable for an early-stage, pre-revenue biotech; direct comparison to revenue-generating peers is misleading. Likely trades at a discount to more advanced clinical-stage biotechs due to its micro-cap status and early pipeline.

Competitive Advantages

•Proprietary antiviral drug discovery platform.
•CDI-988 as a potential first-in-class oral norovirus treatment.
•Focus on large, unmet medical needs in antiviral markets.

Market Intelligence

Get sentiment, earnings intel, and peer analysis with Premium

What Could Drive COCP Stock Higher?

Near-Term (0-6 months)

•Results from Phase 1b norovirus challenge study (CDI-988) expected (Q2-Q3 2026)
•Q1 2026 Earnings (Estimated early May 2026)

Medium-Term (6-18 months)

•Initiation of Phase 2 studies for CDI-988 or CC-42344 (influenza)
•Potential strategic partnership or licensing deal for pipeline assets

Long-Term (18+ months)

•Successful Phase 3 development and regulatory approval for a lead antiviral candidate
•Disruption of existing antiviral treatment paradigms with novel mechanisms

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for COCP?

✓
Positive Phase 1b clinical data for CDI-988, particularly on efficacy and safety.
✓
Further reduction in cash burn or evidence of efficient capital deployment.
✓
Announcement of a strategic partnership or licensing agreement for any pipeline asset.

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Cocrystal Pharma Inc (COCP)?

As of April 2, 2026, Cocrystal Pharma Inc has a DVR Score of 6.4 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Cocrystal Pharma Inc?

Cocrystal Pharma Inc's market capitalization is approximately $13.8M..

What is the risk level for COCP stock?

Our analysis rates Cocrystal Pharma Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

Is Cocrystal Pharma Inc's revenue growing?

Cocrystal Pharma Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.

Is COCP stock profitable?

Cocrystal Pharma Inc has a profit margin of 0.0%. The company is currently unprofitable.

How often is the COCP DVR analysis updated?

Our AI-powered analysis of Cocrystal Pharma Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 2, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for COCP (Cocrystal Pharma Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.